News > General > Consistent survival benefit with ricociclib in the firstline treatment of pre- or perimenopausal women with HR+/HER2-advanced breast cancer

Consistent survival benefit with ricociclib in the firstline treatment of pre- or perimenopausal women with HR+/HER2-advanced breast cancer

February 2021 General Ariez

To view this article please log in on top of screen.

Consistent survival benefit with ricociclib in the firstline treatment of pre- or perimenopausal women with HR+/HER2-advanced breast cancer

Share this article